PL4094754T3 - Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom - Google Patents
Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobomInfo
- Publication number
- PL4094754T3 PL4094754T3 PL22186334.3T PL22186334T PL4094754T3 PL 4094754 T3 PL4094754 T3 PL 4094754T3 PL 22186334 T PL22186334 T PL 22186334T PL 4094754 T3 PL4094754 T3 PL 4094754T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- treatment
- diseases related
- protein aggregation
- preventing diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382439 | 2018-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4094754T3 true PL4094754T3 (pl) | 2026-01-05 |
Family
ID=62716030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22186334.3T PL4094754T3 (pl) | 2018-06-19 | 2019-06-19 | Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom |
| PL19730826.5T PL3810128T3 (pl) | 2018-06-19 | 2019-06-19 | Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19730826.5T PL3810128T3 (pl) | 2018-06-19 | 2019-06-19 | Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210251953A1 (pl) |
| EP (2) | EP3810128B1 (pl) |
| JP (2) | JP2021528442A (pl) |
| CN (2) | CN118845759A (pl) |
| AU (1) | AU2019291061B2 (pl) |
| BR (1) | BR112020026066A2 (pl) |
| CA (1) | CA3103834A1 (pl) |
| DK (1) | DK3810128T3 (pl) |
| ES (2) | ES3044215T3 (pl) |
| HR (1) | HRP20251214T1 (pl) |
| MX (1) | MX2020014070A (pl) |
| PL (2) | PL4094754T3 (pl) |
| PT (1) | PT3810128T (pl) |
| RS (1) | RS67299B1 (pl) |
| SM (1) | SMT202500382T1 (pl) |
| WO (1) | WO2019243453A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| PL4094754T3 (pl) * | 2018-06-19 | 2026-01-05 | Universidad Pablo De Olavide | Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| EP3988096A1 (en) | 2020-10-26 | 2022-04-27 | Universidad Pablo de Olavide OTRI | Sulfated c19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases |
| CN112552272B (zh) * | 2020-12-22 | 2023-06-27 | 四川大学 | 香豆素类化合物及其制备方法和应用、药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9603325D0 (en) | 1996-02-16 | 1996-04-17 | Imperial College | A compound |
| US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
| JP4320089B2 (ja) * | 1999-07-06 | 2009-08-26 | あすか製薬株式会社 | フェニルスルファメート誘導体 |
| DE60124730T2 (de) * | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| GB0511190D0 (en) * | 2005-06-01 | 2005-07-06 | Sterix Ltd | Use |
| ES2514140B1 (es) | 2013-03-26 | 2015-08-03 | Universidad Pablo De Olavide | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento |
| MX2017007095A (es) * | 2014-12-05 | 2017-11-17 | An2H Discovery Ltd | Metodos y composiciones de activacion de la ligasa parkin. |
| MX2018005352A (es) | 2015-10-30 | 2018-08-14 | Ultragenyx Pharmaceutical Inc | Metodos y composiciones para el tratamiento de amiloidosis. |
| US10780094B2 (en) * | 2016-07-22 | 2020-09-22 | New York University | Use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders |
| PL4094754T3 (pl) * | 2018-06-19 | 2026-01-05 | Universidad Pablo De Olavide | Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom |
-
2019
- 2019-06-19 PL PL22186334.3T patent/PL4094754T3/pl unknown
- 2019-06-19 WO PCT/EP2019/066271 patent/WO2019243453A1/en not_active Ceased
- 2019-06-19 EP EP19730826.5A patent/EP3810128B1/en active Active
- 2019-06-19 RS RS20250996A patent/RS67299B1/sr unknown
- 2019-06-19 CN CN202410870792.1A patent/CN118845759A/zh active Pending
- 2019-06-19 CN CN201980054686.3A patent/CN112601521A/zh active Pending
- 2019-06-19 BR BR112020026066-5A patent/BR112020026066A2/pt unknown
- 2019-06-19 JP JP2020571600A patent/JP2021528442A/ja active Pending
- 2019-06-19 AU AU2019291061A patent/AU2019291061B2/en active Active
- 2019-06-19 ES ES22186334T patent/ES3044215T3/es active Active
- 2019-06-19 PT PT197308265T patent/PT3810128T/pt unknown
- 2019-06-19 US US17/253,378 patent/US20210251953A1/en not_active Abandoned
- 2019-06-19 SM SM20250382T patent/SMT202500382T1/it unknown
- 2019-06-19 CA CA3103834A patent/CA3103834A1/en active Pending
- 2019-06-19 ES ES19730826T patent/ES2931815T3/es active Active
- 2019-06-19 HR HRP20251214TT patent/HRP20251214T1/hr unknown
- 2019-06-19 EP EP22186334.3A patent/EP4094754B1/en active Active
- 2019-06-19 DK DK19730826.5T patent/DK3810128T3/da active
- 2019-06-19 PL PL19730826.5T patent/PL3810128T3/pl unknown
- 2019-06-19 MX MX2020014070A patent/MX2020014070A/es unknown
-
2024
- 2024-02-22 JP JP2024025631A patent/JP2024059803A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20251214T1 (hr) | 2025-12-19 |
| EP4094754C0 (en) | 2025-08-06 |
| MX2020014070A (es) | 2021-05-27 |
| PL3810128T3 (pl) | 2023-01-30 |
| BR112020026066A2 (pt) | 2021-03-23 |
| PT3810128T (pt) | 2022-11-09 |
| EP3810128B1 (en) | 2022-08-03 |
| AU2019291061A1 (en) | 2021-02-04 |
| RS67299B1 (sr) | 2025-11-28 |
| EP4094754B1 (en) | 2025-08-06 |
| CN112601521A (zh) | 2021-04-02 |
| US20210251953A1 (en) | 2021-08-19 |
| ES2931815T3 (es) | 2023-01-02 |
| CN118845759A (zh) | 2024-10-29 |
| JP2021528442A (ja) | 2021-10-21 |
| DK3810128T3 (da) | 2022-10-31 |
| EP3810128A1 (en) | 2021-04-28 |
| AU2019291061B2 (en) | 2025-04-10 |
| CA3103834A1 (en) | 2019-12-26 |
| JP2024059803A (ja) | 2024-05-01 |
| ES3044215T3 (en) | 2025-11-26 |
| SMT202500382T1 (it) | 2025-11-10 |
| EP4094754A1 (en) | 2022-11-30 |
| WO2019243453A1 (en) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4094754T3 (pl) | Kompozycje do leczenia chorób związanych z agregacją białek i/lub zapobiegania takim chorobom | |
| IL280710A (en) | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy | |
| IL283042A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| PL3661954T3 (pl) | Muteiny interleukiny 21 i sposoby leczenia | |
| EP3349783C0 (en) | COMPOSITIONS AND METHODS ASSOCIATED WITH THE TREATMENT OF DISEASES | |
| IL268850A (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| EP3263132C0 (en) | Composition for treating il-6-related diseases | |
| SI3377637T1 (sl) | Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože | |
| CL2018001652A1 (es) | Composiciones y métodos para disminuir la expresión de tau | |
| EP3784260A4 (en) | Compositions for the treatment of skin conditions | |
| PL3484469T3 (pl) | Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych | |
| EP3914231A4 (en) | Treatment of skin disorders with topical tapinarof combination compositions | |
| PL3381451T3 (pl) | Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej | |
| EP3790563A4 (en) | Compositions for the treatment of skin conditions | |
| IL269158A (en) | Compositions and methods for treating inflammatory diseases | |
| IL281938A (en) | Stable semaglutide compositions and uses thereof | |
| EP3600285A4 (en) | TOPICAL COMPOSITIONS AND METHODS OF TREATMENT | |
| EP3541401A4 (en) | TREATMENT OF RESPIRATORY TRACT INFECTIONS AND DISEASES WITH GLUTATHION COMPOSITIONS | |
| EP3582768A4 (en) | CANNABINOID FORMULATIONS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASES | |
| EP3398437A4 (en) | PESTICIDE COMPOSITION CONTAINING METCONAZOLE FOR PREVENTING AND TREATING FUSARIOSIS OF PPE AND ITS APPLICATION | |
| IL269550A (en) | Compositions and methods for treating synucleinopathies | |
| EP3592377A4 (en) | TISSUE KALLICREIN DOSAGE FORMS 1 | |
| EP3775261A4 (en) | TARGET BOND FRACTION COMPOSITIONS AND METHODS OF USE | |
| EP3347034A4 (en) | COMPOSITIONS AND METHODS OF PREVENTING AND TREATING HORN SKIN AND SCARCING |